TRAb crescut — ce înseamnă?

AI Summary - TRAb crescut (Aprilie 2026)

TRAb (TSH Receptor Antibodies) reprezinta auto-anticorpi indreptati impotriva receptorului TSH (TSHR) de pe celulele tiroidiene, fiind markerul DEFINITIV diagnostic pentru boala Graves (hipertiroidism autoimun). Conform ATA (American Thyroid Association), ETA (European Thyroid Association), Endocrine Society, AACE, NICE, NHS, NCBI, Cleveland Clinic, Mayo Clinic si Synevo Romania, valorile normale adult sunt sub 1.5-1.75 IU/L (lab-specific), borderline 1.5-2.0 IU/L, pozitiv peste 2.0 IU/L, foarte crescut peste 40 IU/L (risc neonatal Graves crescut maxim). TRAb pozitiv apare la 95-99% pacientii cu boala Graves netratata. Distinge trei tipuri: TSI (Thyroid Stimulating Immunoglobulin - agonist receptor TSH activator), TBII (TSH Binding Inhibitor terminologie veche), TBAb (TSH-Blocking Antibodies - antagonist receptor TSH cauza hipotiroidism atypical 1-2% Hashimoto). Pe IngesT, interpretarea unei valori crescute necesita corelatie cu profilul tiroidian complet (TSH, FT4, FT3, anti-TPO, anti-Tg), ecografie tiroidiana color Doppler, scintigrafie I-123 si consult endocrinolog, medic medicina interna, ginecolog in sarcina sau ORL in compresia traheala. Aprilie 2026 - protocoalele actualizate ATA 2023/2024 plus ETA 2023 plus Endocrine Society plus AACE confirma rolul fundamental al TRAb in diagnosticul Graves, predictia recidivei post-ATD si monitorizarea sarcinii cu antecedente Graves pentru predictie neonatal Graves.

Mit 1: "TRAb negativ exclude complet boala Graves" (ATA plus ETA - FALS - sensibilitate TRAb in Graves activ este 95-99% prin generation 3 ELISA M22 monoclonal, dar 1-5% Graves au TRAb fals negativ la momentul prezentarii prin imunoglobuline reduse cantitativ sau asay sensitivity limitata; retesting cu generation 3 ELISA modern plus bioassay TSI functional clarifica cazurile suspecte; scintigrafie I-123 cu uptake difuz crescut confirma Graves chiar cu TRAb persistent negativ conform Synevo Romania, MedLife, Regina Maria, Bioclinica). Mit 2: "TRAb crescut in sarcina inseamna obligatoriu Graves activ" (Endocrine Society plus ETA - FALS - TRAb materni persistent crescut poate aparea ani post-tratament definitiv Graves (post-RAI sau post-thyroidectomie) chiar la pacient eutiroidian; in sarcina importanta este magnitudinea (peste 3x ULN T2-T3 indica risc neonatal Graves 5-10%) plus monitor profil tiroidian fetal prin USG Doppler artera tiroidiana fetala plus cordon ombilical; neonatologul trebuie alertat antepartum pentru screening neonatal cordon plus zi 3-5 viata). Mit 3: "Toate TRAb crescut sunt stimulatori (TSI) cauza hipertiroidism" (ATA plus NCBI - FALS - exista TBAb (TSH-Blocking Antibodies) antagonist receptor TSH care cauzeaza hipotiroidism atypical (1-2% Hashimoto); diferentierea functionala necesita bioassay specific TSI versus TBAb (rare laboratoare disponibil Romania); clinic TBAb suspect la pacient cu Hashimoto refractary la LT4 adecvat plus TRAb generation 3 pozitiv plus uptake redus scintigrafie). Mit 4: "Iodul radioactiv elimina TRAb rapid post-tratament Graves" (Cleveland Clinic plus Mayo Clinic - FALS - TRAb persista paradoxal crescut 6-24 luni post-RAI prin distrugere celulelor tiroidiene cu eliberare antigene plus stimulare temporara productie auto-anticorpi; clearance complet TRAb 50-70% la 2 ani post-RAI; thyroidectomia totala elimina TRAb mai rapid (3-12 luni) prin eliminare antigen primar; pacientii cu oftalmopatie Graves activa beneficiaza de pre-RAI corticosteroid profilactic pentru prevenire agravare orbitopatie). Mit 5: "Antitiroidianele scad TRAb predictibil la toti pacientii" (ETA plus AACE - FALS - antitiroidianele (metimazol, PTU) au efect imunomodulator modest pe TRAb (scadere 30-50% in 12-18 luni cura); 30-50% pacientii nu obtin remisiune TRAb si recidiveaza la 1-2 ani post-discontinuare; predictori recidiva: TRAb peste 2x ULN la finalul curei, gusa mare, varsta tanara, smoker, oftalmopatie activa, sex masculin, polimorfism CTLA4/PTPN22; algoritm modern includ scor GREAT (Graves Recurrent Events After Therapy) per ETA 2018 pentru decizie tratament definitiv RAI/chirurgie versus cura repetata ATD). Pe IngesT, accesul rapid la specialist endocrinolog plus medicina interna plus ginecolog (sarcina cu Graves) plus oftalmolog (Graves orbitopathy) plus laboratoare specializate (Synevo Romania, MedLife, Regina Maria, Bioclinica, Medicover) este coordonat prin platforma cu telemedicina plus reminder-uri automate SMS pentru monitorizare TSH/FT4 Q4-6 saptamani in faza activa Graves sau anual post-tratament definitiv stabil.

Epidemiologie - prevalenta boala Graves plus alte cauze TRAb crescut

Conform ATA (American Thyroid Association), ETA (European Thyroid Association), Endocrine Society, NCBI si Societatea Romana de Endocrinologie, boala Graves este cea mai frecventa cauza hipertiroidism (70-80% cazuri) si principala situatie clinica cu TRAb crescut. Prevalenta boala Graves: 0.5-1% adulti general populatie globala; in Romania prevalenta 1-1.5% adulti (mai mare in zone iodate insuficient istoric pre-iodare sare); incidenta 20-50 cazuri/100.000/an; raport femei:barbat 5-10:1 (femei dramatic mai frecvent afectate); peak prevalenta 30-50 ani (poate aparea orice varsta); pediatric rare (5% sub 18 ani); senil rare dar atipic cu manifestari predominant cardiace. TRAb pozitiv in Graves netratat: 95-99% sensibilitate generation 3 ELISA M22 monoclonal (cea mai folosita clinic); generation 2 ELISA porcine TSHR sensibilitate 85-90% (utilizat mai rar Romania); bioassay TSI functional sensibilitate similar gen 3 plus specificitate inalta pentru TSI activator versus TBAb blocker (rare laboratoare disponibil Romania). Pseudo-pozitivitate tranzitorie TRAb: tiroidita postpartum 50% pozitiv tranzitor (resoluție 6-12 luni postpartum); tiroidita silentă autoimună 30% pozitiv tranzitor moderate; Hashimoto 5-15% TRAb pozitiv (Hashitoxicoza variant agresiv overlap Graves); post-iod radioactiv 60-80% TRAb crescut tranzitor 6-12 luni post-RAI (clearance complet 50-70% la 2 ani); post-LT4 over-replacement rare pseudo-pozitive falsely (la pacient sensibil cu cross-reactivity). TRAb-blocking antibodies (TBAb): rare 1-2% Hashimoto cu TRAb pozitiv functional blocking (cauza hipotiroidism atypical mai severa); distinge prin bioassay specific TSI versus TBAb. Hipertiroidism non-autoimun cu TRAb majoritar negativ: nodul autonom (Plummer adenom toxic) 5-10% hipertiroidism cazuri; gușă multinodulară toxică 10-15% (varstnici dominant); tiroidită destruction Quervain/postpartum/silent (transient tireotoxicoza); tireotoxicoza factice rare (drug supplementation LT4 exogenă); struma ovarii rare (ectopic tiroidian în teratom); tireotoxicoza chorionic rare (sarcina molara, choriocarcinom HCG-mediated TSHR cross-reactivity).

Cresterea expunerii ultimii 30 ani: prevalenta boala Graves a crescut moderat prin imbatranirea populatiei plus polipharmacy plus stress chronic plus expunere endocrine disruptors (pesticide, bisphenol A, perchlorate, perfluoroalkyl substances PFAS); incidenta crescuta in zone post-Cernobil cu expunere I-131 ambientala (Belarus, Ucraina, Romania de Nord-Est); incidenta crescuta post-tsunami Fukushima (Japonia); cresterea cazurilor amiodarona-induced thyrotoxicosis (cardiologie cu amiodarona cronic la tot mai multi pacienti AFib plus aritmii); cresterea cazurilor imunoterapie checkpoint inhibitor-induced thyroiditis cu fază tireotoxica (oncologie cu pembrolizumab, nivolumab, ipilimumab tot mai utilizat); cresterea cazurilor IFN-α induced thyroid autoimmunity (hepatologie cu hepatita C cronica plus IFN treatment); cresterea cazurilor alemtuzumab-induced Graves (neurologie scleroza multipla cu alemtuzumab tratament 30-40% dezvolta Graves la 2-3 ani post-tratament). Trigerii moderni emergent identificati: COVID-19 post-infectia 0.5-1% dezvolta Graves de novo prin mimicry molecular SARS-CoV-2 spike protein cu TSHR plus activare imunitate adaptive; vaccinare COVID rar Graves de novo raportat (cauzalitate incerta); stresul psihologic acut cronic prin pandemia 2020-2024 plus razboi Ukraina 2022 plus criza energetică 2022-2024 a crescut declanşatori Graves; deficit vitamina D cronic (sub 30 ng/mL) corelat cu risc Graves crescut 2-3x; deficit selenium (sub 70 μg/L) corelat cu Graves orbitopathy mai severa plus raspuns selenium 200 μg/zi modest la EUGOGO trial; microbiom intestinal disbiotic corelat cu risc autoimmune general inclusiv Graves (probiotic intervention emergent cercetare).

Patofiziologie - mecanisme autoimune Graves plus alte boli TRAb pozitive

Conform NCBI, ATA, ETA, Endocrine Society, Mayo Clinic plus AACE, boala Graves este o boala autoimuna sistemica cu predilectie tiroidiana, mediata de T cells plus B cells reactivi impotriva receptorului TSH (TSHR). Mecanism autoimun central Graves: Loss of self-tolerance la TSHR prin defect thymic deletion plus peripheral tolerance breakdown (Treg deficient functional plus polimorfisme CTLA4/PD-1/PTPN22/CD40); T cell activation CD4+ Th1/Th17 reactivi TSHR prin presentation epitope HLA-DR3/DR4/B*8 (susceptibility); B cell activation in germinal centers tiroidieni cu maturare productie auto-anticorpi TRAb high-affinity tip IgG1 (predominant) plus IgG3; TRAb agonist actiune (TSI) - leaga TSHR ectodomain similar TSH endogena dar fara reglare feedback negativ (TRAb persista in circulatie zile-saptamani); activare cAMP intracelular plus PKA plus phospho CREB plus transcription gene tiroidian (Tg, TPO, NIS, dehalogenaza); hiperplazia plus hipertrofia tiroidian cu gușă difuză vascularizată (semn furcuza vascular auscultat); hiperproductie hormoni tiroidieni T4/T3 cu suprimare TSH feedback hipofizar plus tablou hipertiroidism. Mecanism orbitopatia Graves (50%): orbital fibroblasts exprima TSHR (cross-reactivity tisulara cu tiroidiene); TRAb leaga TSHR orbital plus IGF-1R (insulin-like growth factor receptor cu antagonist teprotumumab terapeutic modern aprobat 2020); activare orbital fibroblasts cu diferenţiere in adipocyte plus hyaluronan synthesis plus colagen deposition; edem retrobulbar plus proptoza plus retracție palpebrală plus oftalmoplegie plus diplopia plus potential neuropatie optic. Mecanism dermopatie Graves (1-3%): pretibial fibroblasts cu TSHR cross-reactivity (similar orbital); deposit mucoid pretibial plus tegument indurat plus aspect orange-peel; asociat tipic Graves severe plus orbitopatie severa. Mecanism acropahie Graves (foarte rare): clubbing digital plus subperiosteal new bone formation plus osteoartrita falangelor terminale prin mechanism similar autoimmune.

Trigerii Graves identificati cu mecanism patofiziologic: Stres major psihic-fizic - cortisolul cronic crescut alterează echilibrul Th1/Th17/Treg cu pondere proinflamatorie plus eliberare antigene tiroidieni prin stres oxidativ; Postpartum (12 luni) - rebound immune post-suprimare fiziologica sarcina (Th2-shift sarcina, Th1-rebound postpartum) plus expunere antigene tiroidieni postpartum thyroiditis-related; Infectii - Yersinia enterocolitica (mimicry molecular Yop proteins cu TSHR), COVID-19 (mimicry SARS-CoV-2 spike protein cu TSHR plus activare imunitate adaptive plus stres oxidativ infectia acuta); EBV plus CMV reactivare cronic posibil declanşator; Sevraj brusc glucocorticoid - eliberare immune supresie pre-existenta; Iod excess (Jod-Basedow) - aport iod brusc crescut (medicatie amiodarona, contrast iodat CT, supplements iod) cauzeaza Graves de novo la susceptibili sau exacerbare Graves preexistent; Drugs immunomodulatori - amiodarona (mecanism dual destruction toxic plus iod excess), IFN-α (autoimmune amplification), alemtuzumab (immune reconstitution Graves 30-40% la 2-3 ani post-tratament SM), checkpoint inhibitors anti-PD1/PD-L1/CTLA4 (immune-related adverse event 5-15% thyroid involvement variabil Graves sau Hashimoto), litiu rare. Genetic predisposition: HLA-B*8 plus HLA-DR3 (Caucasians dominant), HLA-Bw46 plus HLA-DR9 (Asians); CTLA4 polymorphisms (CT60 G allele); PTPN22 R620W (functional gain-of-function tyrosine phosphatase amplifies T cell activation); CD40 polymorphisms; TSHR polymorphisms susceptibility; FOXP3 polymorphisms (Treg dysfunction); antecedente familiale 5-10× risc Graves la rude gradul I plus risc creșterii alte boli autoimune tiroidiene (Hashimoto familial overlap).

Pseudo-pozitivare TRAb cu mecanism patofiziologic: Tiroidita postpartum (50% TRAb tranzitor pozitiv) - rebound immune postpartum cu activare temporara TRAb productie pe fond gestational immune-tolerance shift; resolutie 6-12 luni; surveillance 1-2 ani recidiva Graves; Tiroidita silenta autoimuna (30% TRAb tranzitor) - destruction thyroid autoimmune fara durere (vs Quervain) cu liberare antigene plus TRAb tranzitor; Hashimoto cu TRAb pozitiv (5-15% Hashitoxicoza overlap variant) - subset Hashimoto cu fenotip mixed Hashimoto plus Graves features (anti-TPO+ plus TRAb+ plus uneori hipertiroidism tranzitor); evolutie tipic Hashimoto cu hipotiroidism final; Sarcina cu transfer TRAb materni fetal - traversare placentara TRAb materni T2-T3 (peak T3); neonatal Graves la TRAb materni peste 3× ULN risc 5-10% (tablou neonatal hipertiroidism tahicardie IUGR prematuritate hidrops fetal); auto-resolutie 2-3 luni postpartum (clearance TRAb materni); Post-iod radioactiv (RAI) Graves - eliberare antigene tiroidieni destruction plus stimulare temporara productie TRAb 6-12 luni; clearance 50-70% la 2 ani; pacient cu oftalmopatia Graves activa: pre-RAI corticosteroid profilactic; Post-thyroidectomia totala Graves - eliminare antigen primar tiroidian; TRAb clearance mai rapid 3-12 luni; orbitopatia poate persista sau chiar progresa post-thyroidectomie (paradox); Post-LT4 over-replacement - rare pseudo-pozitive falsely la pacient sensibil cu cross-reactivity asay; switching asay generation 3 modern clarifica; Heterophile antibodies interferenta - false pozitive sau false negative; rare suspect cu retest dilution sau heterophile-blocking tube; Biotin interference - biotin supplements high-dose (peste 10 mg/zi) interfera cu ELISA streptavidin-biotin; pauza biotin 48h pre-test recomandat.

Cauze TRAb crescut - clasificare etiologica completa

Conform ATA, ETA, Endocrine Society, AACE, NICE, NHS, Cleveland Clinic, Mayo Clinic plus Societatea Romana de Endocrinologie, cauzele TRAb crescut se clasifica multifactorial. (1) Boala Graves (cea mai frecventa cauza - 80-90% cazuri TRAb pozitiv clinical relevant): Hipertiroidism autoimun primary - tipic gușă difuză vascularizată plus uptake difuz crescut 24-50% I-123 scintigrafie plus profil hormonal hipertiroidism (TSH suprimat sub 0.1, FT4 plus FT3 crescut); incidenta 20-50/100.000/an; femei:barbat 5-10:1; peak 30-50 ani; rare pediatric 5%; senil dominant cardiac manifestari. Graves cu oftalmopatia Graves (orbitopathy GO 50% cazuri Graves) - proptoza, retractie palpebrala, lid lag, oftalmoplegie cu diplopia, edema periorbital, durere oculara, vedere imblanzita, severe neuropatia optic; clasificare EUGOGO 2008/2021 - faza activa CAS (Clinical Activity Score) versus inactiva reziduala; severitate ușoară-moderată-severă; activitate clinicala determină tratament. Graves cu dermopatia pretibială (1-3% Graves severe) - placi indurate fibroza pretibial plus aspect orange-peel; asociat tipic Graves severe plus orbitopatie severa; rare cu acropahie. Graves cu acropahie (foarte rare) - clubbing digital plus subperiosteal bone formation plus osteoartrita falangelor terminale.

(2) Tiroidita autoimuna postpartum cu TRAb tranzitor (50% pozitiv): incidenta 5-10% postpartum femei; faza tireotoxica 1-6 luni postpartum (anti-TPO+ tipic plus TRAb tranzitor 50% cazuri); faza hipotiroidiană 6-12 luni; rezoluție 80% cazuri; permanent hipotiroidism 20-30% cu necesitate LT4 lifelong; surveillance 1-2 ani recidiva Graves; risc recurenta postpartum 70% gestatie ulterioara. (3) Tiroidita silentă autoimună (30% TRAb tranzitor): forma rare tireotoxica nedureros versus Quervain dureros; auto-resoluție majoritar fara tratament; rare pacienti dezvoltă hipotiroidism permanent. (4) Hashimoto cu TRAb pozitiv (Hashitoxicoza overlap variant 5-15%): subset Hashimoto cu fenotip mixed Hashimoto plus Graves features; anti-TPO+ predominant plus TRAb+ plus uneori hipertiroidism tranzitor pana evolutie Hashimoto cu hipotiroidism cronic; tratament initial β-blocant tireotoxic phase apoi LT4 hipo phase. (5) Tiroidite IFN-α/amiodarona/checkpoint inhibitor induced cu TRAb pozitiv: amiodarona-induced thyrotoxicosis type 1 (Graves-like, iod-excess Jod-Basedow mechanism) - TRAb pozitiv tipic - tratament metimazol high-dose plus stop amiodarona daca posibil cardiologic; amiodarona-induced thyrotoxicosis type 2 (destruction toxic) - TRAb negativ tipic - tratament glucocorticoid plus β-blocant; IFN-α induced thyroid autoimmunity (Graves sau Hashimoto pattern) - TRAb pozitiv in pattern Graves; checkpoint inhibitor-induced thyroiditis - TRAb majoritar negativ (predominant destruction pattern) dar rare TRAb pozitiv pattern Graves. (6) Sarcina cu antecedente Graves sau Graves activ in sarcina: monitorizare TRAb T2-T3 obligatorie pentru predictie neonatal Graves; TRAb materni peste 3× ULN T2/T3 risc 5-10% neonatal Graves; transfer placentar TRAb cu peak T3; neonatologul alertat antepartum pentru screening neonatal cordon plus zi 3-5 viata; tablou neonatal hipertiroidism tahicardie IUGR prematuritate hidrops fetal; auto-resolutie 2-3 luni postpartum. (7) Post-iod radioactiv (RAI) Graves: TRAb crescut paradoxal tranzitor 6-12 luni post-RAI prin destruction tiroidian plus eliberare antigene plus stimulare temporara productie auto-anticorpi; clearance complet 50-70% la 2 ani; pacient cu oftalmopatia Graves activa fumator: pre-RAI corticosteroid profilactic (prednison 0.4-0.5 mg/kg/zi 1 luna tapering 2-3 luni) pentru prevenire agravare orbitopatie. (8) Post-thyroidectomia totala Graves: TRAb clearance mai rapid 3-12 luni (vs RAI mai lent); 5-10% cazuri TRAb persistent crescut 1-2 ani prin antigene tiroidieni reziduali sau anti-cleaved TSHR antibodies (rol incert); orbitopatia poate persista sau chiar progresa paradoxal post-thyroidectomie. (9) Tireotoxicoza factice (rare suspect): drug supplementation LT4 exogena - tireoglobulina scazut distinge (vs Graves tireoglobulina crescut); profil pharmacologic LT4 detectat plasma; TRAb negativ tipic dar rare pseudo-positive prin cross-reactivity asay. (10) Marine-Lenhart syndrome (Graves plus nodul autonom): cazuri rare combinatie Graves plus nodul autonom Plummer; uptake heterogen scintigrafie (difuz Graves plus focal hot nodule); TRAb pozitiv Graves component; tratament combinatie ATD plus RAI sau chirurgie selectiv.

Tablou clinic - manifestari hipertiroidism Graves dominant

Conform Mayo Clinic, Cleveland Clinic, NCBI, ATA, ETA plus Endocrine Society, manifestarile clinice TRAb crescut sunt dominate de tabloul hipertiroidism cu Graves predominant (80-90% cazuri TRAb pozitiv clinical relevant). Simptomatic clasic hipertiroidism: Cardiac - palpitatii, tahicardie sinusala persistenta (peste 90-100 bpm repaus), aritmii (AFib 10-20% Graves, varstnici peste 50% risc AFib), hipertensiune sistolica izolata, insuficienta cardiaca thyrotoxic cardiomyopathy severe untreated, risc tromboembolism (AFib plus thyrotoxicoza); Neuropsihiatric - anxietate severa, iritabilitate, insomnia, depresia atipica, tremor fin distal mâinilor (caracteristic), agitatie psihomotorie, scaderea concentrarii cu deficit cognitiv reversibil, psihoza tireotoxica rare; Metabolic - intoleranta cald, transpiratii excesive, scadere ponderala inexplicabila cu apetit crescut sau normal (paradox), polidipsie compensatorie, glicemie crescuta paradoxal (rezistenta insulin temporar), lipide modeste scazute, hyperaldosteronism secundar contribuie hipertensiune; Musculo-scheletic - slabiciune musculara proximala (miopatie tireotoxica - urcat scari dificil, ridicat din scaun), atrofie musculara distal severe untreated, osteoporoza accelerata cu risc fracturi (vertebrale, sold) mai ales post-menopauză, pierdere osoasă rapida sub LT4 over-replacement pseudo-thyrotoxicoza iatrogenic; Gastrointestinal - diaree, tranzit accelerat, malabsorbtie marginal, greata rare; Reproductiv - tulburari menstruale (oligomenoree, amenoree), disfuncție erectilă, scaderea libidoului, infertilitate, ginecomastia rare barbati; Tegumentar - tegument cald, umed, fine, onicoliza (Plummer nails - ridicare unghie de la patul ungheal), vitiligo asociere autoimmune, par fin cu alopecie diffuza posibila, hiperhidroza palmara/plantara; Ophthalmic non-Graves - lid lag plus retractie palpebrala generic hipertiroidism (vs proptoza Graves-specific).

Semne specifice Graves (vs alte hipertiroidisme): Gusa difuza vasculara - tiroida marit difuz simetric tipic moderate dimensiuni (2-3x normal), elastica plus vasculara (suflu vascular auscultat cu stetoscopul plus thrill palpatoriu rare); ecografie color Doppler hipervascular ("thyroid inferno" sign caracteristic); rare gusa enorma cu compresia traheala/esofagiana necesitand chirurgie urgent. Oftalmopatia Graves (50% cazuri Graves): proptoza (exophthalmos) - protruzie ochi peste 22 mm Hertel exophthalmometer (variabil rasial; bilateral simetrica tipic, rare unilateral 10%); retractie palpebrala (von Graefe sign - lid lag at downgaze plus Kocher sign - staring expression); oftalmoplegie restrictiva cu diplopia (fibroza muschilor extraoculari, dominant inferior plus medial rectus); edema periorbital plus chemosis conjunctival; durere oculara plus senzatie corp strain plus fotofobia; vedere imblanzita progresiv plus pierdere campului vizual; severe untreated - neuropatia optic compresiva cu pierdere acuitate vizual ireversibila (5% Graves orbitopatie severa); exposure keratopathy cu ulcerare corneana rare; clasificare EUGOGO 2008/2021 CAS (Clinical Activity Score - 7 items: durere repaus, durere mobilitate, eritem palpebral, eritem conjunctival, edem palpebral, chemosis, caruncle plus plica edema) plus severity (NOSPECS clasic, EUGOGO modern). Dermopatia Graves (1-3% cazuri Graves severe): pretibial mixedema cu placi indurate fibroza tegumentar (aspect orange-peel plus textura ceara), tipic pretibial bilateral simetric; rare extindere extremitati superioare; asociat tipic Graves severe plus orbitopatie severa; tratament corticosteroid topic plus injectional intralesional. Acropahie Graves (foarte rare): clubbing digital plus subperiosteal new bone formation radiografic plus osteoartrita falangelor terminale; asociat Graves severe plus orbitopatie plus dermopatie (triada cutanat-ocular-acral).

Manifestari speciale per grup populational: Pediatric Graves (5% cazuri Graves) - mai puține semne ocular tipic; adesea AFib plus cardiopatie thyrotoxic mai severă (per kg corp); stagnare creștere paradoxal posibilă in plina perioada pubertara; concentrare scolara afectata cu deficit invatare reversibil post-eutiroidian; cura ATD prelungita 24-36 luni preferred vs RAI (concern radiogenic carcinogenesis pe termen lung), chirurgie selectiv. Senil Graves (peste 65 ani) - manifestari atipice predominant cardiace (AFib dominant, IC), apathetic thyrotoxicoza paradoxal (depresia plus apatia in loc anxietate plus agitatie), pierdere ponderala marcata fara apetit crescut, slabiciune musculara confunda cu sarcopenia, osteoporoza accelerata cu risc fracturi, semne ocular minime; tratament dominant RAI plus β-blocant control simptomatic; ATD selectiv prin risc agranulocitoza crescut. Sarcina cu Graves preexistent sau de novo - exacerbare T1 (HCG cross-reactivity cu TSHR plus immune-shift Th2 inadecvat la pacient cu autoimmune severe), ameliorare T2-T3 (immune-tolerance gestational), recidiva postpartum 70% in 1 an; manifestari mascate cu cele fiziologice sarcina (tahicardie sinusala fiziologica, edema, intoleranta cald); tratament PTU T1 plus metimazol T2-T3 (vezi tratament sectiune); RAI absolut CONTRAINDICAT; chirurgie selectiv T2 doar daca necesar absolute. Tireotoxicoza crisis (storm) - emergency endocrinologic mortalitate 10-30%; trigger stres major (infectie, chirurgie, traumatism, sevraj brusc ATD, RAI fara pre-treatment); tablou febra inalta (peste 40°C), tahicardie extrema (peste 140 bpm), AFib plus IC, dehidratare severa, agitatie spre coma, MOF; scor Burch-Wartofsky 1993 sau JTA criteria; tratament: PTU sau metimazol high-dose oral/NG, iodine inorganic (Lugol 8 picaturi Q6h sau KI saturated solution) 1h dupa ATD initial, corticosteroid IV (hydrocortizon 100 mg Q8h sau dexametazon 2 mg Q6h - reduce conversie T4-T3 plus tratament insuficienta suprarenala relativa), β-blocant IV (esmolol perfuzie sau propranolol oral/IV - reduce conversie T4-T3 plus control AFib/tahicardie), cooling pasiv plus acetaminophen (NU aspirina - displace T4 din TBG eliberare T4 libera plus agravare), suport ICU complet (oxygen, IV fluids, plasmapheresis emergent severe refractary). Imunoterapie checkpoint inhibitor-induced Graves - rare (mai des hipotiroidism induced); tratament standard ATD plus β-blocant; continuare imunoterapie posibila daca control eutiroidian; consult endocrinolog plus oncolog coordonat. Amiodarona induced thyrotoxicosis (AIT) - tip 1 Graves-like (iod-excess Jod-Basedow): metimazol high-dose 40-60 mg/zi; uneori stop amiodarona daca cardiologic posibil; tip 2 destruction toxic: glucocorticoid IV plus β-blocant; tip mixed (50% cazuri): combinatie ATD plus glucocorticoid; chirurgie subtotala/totala selectiv refractary.

Diagnostic - algoritm TRAb plus tests adjuvante

Conform ATA 2016/2020/2024 plus ETA 2018/2023 plus AACE plus Endocrine Society 2011, diagnosticul boala Graves necesita algoritm structurat. Diagnostic initial hipertiroidism suspect: TSH - cea mai sensibilă, suprimat sub 0.1 mUI/L in hipertiroidism primary (Graves, nodul autonom, tiroidita destruction); intermediar 0.1-0.4 in hipertiroidism subclinical; central hipertiroidism rare TSH crescut paradoxal (TSH-secretory pituitary adenoma); FT4 (Free T4) - confirmare severity (norma 0.93-1.7 ng/dL la majoritatea laboratoarelor); crescut tipic Graves activ; FT3 (Free T3) - crescut paradoxal mai marcat decat FT4 in Graves activ (T3 toxicosis subtype 5-10% Graves); norma 2.0-4.4 pg/mL; TRAb generation 3 ELISA M22 monoclonal - PRIMA LINIE distinge Graves de alte hipertiroidism cauze; pozitiv peste 2.0 IU/L (lab-specific); foarte crescut peste 40 IU/L (risc neonatal Graves crescut maxim); Anti-TPO plus anti-Tg - asociere autoimmune adițional (anti-TPO pozitiv 70-80% Graves plus 95% Hashimoto; anti-Tg pozitiv 40-60% Graves plus 70-80% Hashimoto); utili distinct in Hashitoxicoza overlap (anti-TPO+ plus TRAb+).

Imagistic standard diagnostic Graves: Ecografie tiroidiana cu Doppler color - Graves activ: tiroida marit difuz (volume 30-100 mL normal 10-20 mL), hipoecogen omogen difuz, hipervascular cu "thyroid inferno" sign (vascularizatie Doppler intens 360°) plus peak systolic velocity inferior thyroid artery crescut peste 80 cm/s; distinge de tiroidita destruction: Hashimoto tipic hipoecogen heterogen cu pseudo-nodulatie plus septă fibroase plus hipovascular; Quervain hipoecogen focal/multifocal cu zone necrotice plus hipovascular; distinge de nodul autonom: nodul focal hot scintigrafie cu suprimare restantă tiroida adiacenta; Scintigrafie tiroidiana I-123 (preferred per ETA 2018) sau Tc-99m pertechnetate (alternative cost-eficient mai folosit Romania) - Graves: uptake difuz crescut 24h I-123 30-50% (normal 5-25%); Tiroidita destruction (Quervain, postpartum, silent): uptake redus sub 5% (no synthesis active, only hormone release pre-stored); Nodul autonom (Plummer): uptake focal cu suprimare restantă; Gușă multinodulară toxică: uptake heterogen focal multipli; Marine-Lenhart syndrome: pattern combinatie Graves diffuse plus focal hot nodule; Note importante: scintigrafie CONTRAINDICATA sarcina (RAI contraindicat) plus alaptare (1-2 saptamani pause); aport iod recent (CT contrast iodat) plus amiodarona cronic plus ATD recent altereaza uptake; Tc-99m versus I-123 diferenta trapping versus organification (rare distinct in Graves dar nodul autonom poate uptake Tc-99m suprimat I-123 - "discordant nodule").

Diagnostic Graves criterii confirmation: hipertiroidism (TSH sub 0.1 plus FT4 sau FT3 crescut) plus TRAb pozitiv (peste 2.0 IU/L lab-specific) = Graves CONFIRMAT; sau hipertiroidism plus ecografie hipervascular ("thyroid inferno" Doppler) plus uptake scintigrafie difuz crescut = Graves CONFIRMAT chiar TRAb pseudo-negativ rare. Distinge diagnostic Graves versus alte hipertiroidism: Graves cu TRAb pozitiv - uptake difuz crescut, ecografie hipervascular, anti-TPO+ ades; Tiroidita destruction cu TRAb negativ - uptake redus, ecografie hipovascular focal/diffuse, anti-TPO+ in postpartum/silent autoimmune sau VSH foarte crescut Quervain; Nodul autonom Plummer cu TRAb negativ - uptake focal hot, ecografie nodul hipoecogen/heterogen hipervascular, distinge de Graves prin focal versus diffuse pattern; Tireotoxicoza factice cu TRAb negativ - tireoglobulina scazut (vs Graves tireoglobulina crescut), profil pharmacologic LT4 detectat plasma; Tireotoxicoza chorionic in sarcina molara - HCG crescut foarte (peste 100.000 IU/L), TRAb negativ, ecografie uter molar; Adenom hipofizar TSH-secretory rare - TSH crescut paradoxal cu FT4/FT3 crescut, MRI hipofizar mass, alfa-glycoprotein subunit crescut. Investigare complicatii Graves: ECG - AFib (anticoagulare urgent), sinus tachycardia, prelungire QT rare; Echocardiografie - cardiomiopatie thyrotoxic severe untreated, regurgitare valvulara secundara, hypertensiune pulmonara secundara; DEXA bone densitometry - osteoporoza risc crescut mai ales post-menopauză; Lipidograma - modest scădere (paradox); Glicemia - rezistenta insulin temporar cu hyperglicemia tranzitorie; Hemograma - anemia mild posibila; VSH plus CRP - normal Graves (vs Quervain VSH crescut peste 50); Function hepatica - aminotransferaze mild crescute Graves activ uneori; Oftalmologic exam complete - obligatoriu pentru Graves orbitopathy: Hertel exophthalmometer, CAS score, severity grading, vizual fields, OCT (optic neuropathy compresive evaluare).

Complicatii - hipertiroidism netratat plus tratament-induse

Conform NCBI, Mayo Clinic, Cleveland Clinic, ATA, ETA, Endocrine Society plus AACE, complicatiile hipertiroidism Graves netratat sau sub-tratat sunt severe plus multisistemic. Cardiovascular dominant: Atrial fibrillation (AFib) - 10-20% Graves general, varstnici peste 50% risc; risc trombembolism crescut cu necesitate anticoagulare orala (warfarină sau DOAC cu mentiune metabolismul accelerat in hipertiroidism necesita doze crescute pana eutiroidian); CHA2DS2-VASc score includ thyrotoxicoza ca factor risc (1 punct); cardioversie selectiv post-eutiroidian (rare AFib persistent necesita ablation); Tahycardia sinus persistenta - peste 100 bpm repaus; risc cardiomyopathy thyrotoxic ireversibila severe untreated; Insuficienta cardiaca - cardiomiopatie thyrotoxic high-output sau low-output severe untreated; reversibila majoritar post-eutiroidian dar 10-15% pacienti raman cu fractie ejectie redusa permanent; Hipertensiune sistolica izolata - prin debit cardiac crescut; rezolva post-eutiroidian; Risc tromboembolism - AFib plus hypercoagulabilitate thyrotoxica (Factor VIII crescut, fibrinogen crescut, von Willebrand factor crescut); risc AVC, embolie pulmonară; Cardiomyopathy thyrotoxic ireversibila - 10-15% pacienti severe untreated; necesitate beta-blocant lifelong plus monitorizare cardiologic chiar post-eutiroidian.

Osteoporoza: pierdere osoasă accelerată prin direct effect T3/T4 pe osteoclastogeneza plus reducere osteoblastogeneza; risc crescut fracturi vertebrale plus sold post-menopauză; reversibila partial post-eutiroidian (cu LT4 over-replacement pseudo-thyrotoxicoza iatrogenic mentine risc cronic); recomandare DEXA baseline plus anual; suplementare calciu 1000-1200 mg/zi plus vitamina D 800-1000 IU/zi; bisphosphonates selectiv (osteoporoza established cu T-score sub -2.5 sau fractura fragility). Endocrin: Diabet decompensat - rezistenta insulin temporar cu hyperglicemia tranzitorie; rezolva post-eutiroidian; Infertilitate - tulburari menstruale anovulatorii; rezolva post-eutiroidian; Tulburari menstruale - oligomenoree, amenoree, menoragia rare; Hyperaldosteronism secundar - contribuie hipertensiune; Adrenal cortisol metabolism alterare - cortisol metabolism crescut cu insuficienta suprarenala relativa storm risc; Disfuncție erectilă plus libido scazut - reversibila post-eutiroidian. Neuropsihiatric: Anxietate severa, depresia atipica - frecvent diagnostic eronat psihiatric pre-recunoastere thyrotoxicoza; rezolva post-eutiroidian; Psihoza tireotoxica rare - severe untreated, mimează schizofrenia plus mania bipolara; Tremor invalidant - poate persista mild post-eutiroidian rare; Deficit cognitiv reversibil - "thyrotoxic brain fog" cu scaderea concentrarii plus memoria pe termen scurt; reversibil post-eutiroidian luni; Crize convulsive rare - severe untreated sau storm.

Tireotoxicoza crisis (thyroid storm) - emergency endocrinologic: mortalitate 10-30% chiar cu tratament agresiv; Trigger: stres major (infectie, chirurgie, traumatism, naştere, sevraj brusc ATD, RAI fara pre-treatment, DKA, AVC, AMI); Tablou clinic: febra inalta peste 40°C (caracteristic - dar absenta nu exclude); tahycardia extrema peste 140 bpm; AFib cu RVR sau alte aritmii severe; insuficienta cardiaca acuta congestiva; dehidratare severa cu hipotensiune posibila; agitatie psihomotorie spre coma; greata, varsaturi, diaree, dureri abdominale; icter rare (insuficienta hepatica); MOF (multi-organ failure); Scor Burch-Wartofsky 1993 (peste 45 punctaj indica storm) sau JTA (Japan Thyroid Association) criteria (combinatie clinica plus laborator); Tratament emergent: PTU 200 mg PO/NG Q4-6h SAU metimazol 60-80 mg/zi (PTU preferred prin block T4-T3 conversion peripheral plus mai sigur acut); iodine inorganic 1h dupa ATD initial - Lugol 8 picaturi Q6h SAU KI saturated solution 5 picaturi Q6h SAU sodium iodide 0.5-1 g IV (Lugol preferred Romania disponibil); corticosteroid IV - hydrocortizon 100 mg Q8h SAU dexametazon 2 mg Q6h (reduce conversie T4-T3 plus tratament insuficienta suprarenala relativa); β-blocant IV - esmolol perfuzie 50-200 μg/kg/min titrat HR sub 100 SAU propranolol 1 mg IV slow Q5 min plus oral 40-80 mg Q4-6h (reduce conversie T4-T3 plus control AFib/tahycardia); cooling pasiv - bath rece, ice packs, acetaminophen (NU aspirina - displace T4 din TBG eliberare T4 libera plus agravare); suport ICU complet - oxygen terapie, IV fluids cu monitorizare CVP, electrolyte correction; plasmapheresis emergent severe refractary; thyroidectomia emergent severe refractary la 24-48h tratament medical maximal.

Oftalmopatia Graves severa: Pierdere acuitate vizual - severe untreated; Compresia nerv optic (DON - Dysthyroid Optic Neuropathy) - 5% Graves orbitopatie severa; emergency oftalmologic; tratament glucocorticoid IV pulse (methylprednisolone 500-1000 mg/zi 3 zile consecutive) plus decompression orbital chirurgical urgent; Diplopia persistenta - oftalmoplegie restrictiva fibroza muschilor extraoculari; rezolva partial post-eutiroidian plus tratament; rare necesita strabismus surgery; Exposure keratopathy plus ulcerare corneana - severe proptoza cu inchidere palpebrala incompleta; tratament lubrifianti intensive plus tarsorrhaphy chirurgical selectiv; Disfuncționalitate sociala plus profesionala - prin diplopia plus aspect cosmetic alterat; suport psihologic obligatoriu; Faza inactiva reziduala - chirurgie rehabilitative dupa stabilizare 6-12 luni faza activa: decompression orbital pentru proptoza reziduala, strabismus surgery pentru diplopia reziduala, oculoplastic blepharoplasty pentru retractie palpebrala reziduala plus cosmetic restoration.

Tratament-induced complicatii: Hipotiroidism post-tratament definitiv - 50-80% Graves dezvolta hipotiroidism post-RAI sau thyroidectomia; necesita LT4 substituire lifelong cu titrare TSH 0.4-2.5 mUI/L tinta; Recidiva Graves post-ATD - 30-50% recidiveaza la 1-2 ani post-discontinuare ATD 12-18 luni cura; predictori: TRAb persistent peste 2× ULN la finalul curei, gusa mare, varsta tanara, smoker, oftalmopatie activa, sex masculin, polimorfisme genetice CTLA4/PTPN22; Agranulocitoza ATD (rare 0.1-0.5%) - severitate vital threatening prin infectii oportuniste; oprire ATD imediata plus G-CSF plus antibiotice profilactic empiric plus consultatii hematologic urgent; switch la alta strategie definitiva (RAI sau chirurgie); Hepatotoxicitate ATD - mild aminotransferaze crescute 5-30% (continuare cu monitorizare); severe fulminant hepatic failure rare cu PTU (necesitate transplant hepatic); recomandare functie hepatica baseline plus monitorizare; Vasculita ANCA-pozitiva - rare PTU plus metimazol, manifestare cutanata, renala, pulmonara; oprire ATD plus tratament glucocorticoid; Embriopatie metimazole T1 - aplasia cutis congenital, choanal atresia, esophageal atresia, omphalocele, dysmorphic facies; recomandare PTU T1 plus switch metimazol T2-T3 daca posibil; Hipoparatiroidism post-thyroidectomia - 1-2% permanent (mai mult tranzitor 10-20%); necesita calciu plus calcitriol lifelong; Paralizie laringeu recurent - 1-2% unilateral post-thyroidectomia (rare bilateral cu necesitate tracheostomy); Agravarea oftalmopatia Graves post-RAI - 15-20% cazuri; pre-RAI corticosteroid profilactic la fumator plus oftalmopatie activa.

Tratament Graves - 3 optiuni clasice plus adjuvante

Conform ATA 2016/2020/2024, ETA 2018/2023, AACE plus Endocrine Society 2011, tratamentul boala Graves dispune de 3 OPTIUNI CLASICE majore, decizia fiind individualizata. Optiunea 1 - Antitiroidian (Antithyroid Drug, ATD) prima linie majoritar: Metimazol (Tirozol, Thiamazole, Tapazole) - PRIMA LINIE majoritar adult plus pediatric; Doza initiala: 10-30 mg/zi (mild 10-15 mg, moderate 20-30 mg, severe 30-60 mg); Maintenance: 5-10 mg/zi titrat dupa TSH/FT4 monitorizare Q4-6 saptamani initial apoi Q3 luni; Doza zilnica unica avantaj complianta versus PTU 3x/zi; Avantaje: mai siguran hepatic (vs PTU), eficient blocare TPO plus organification plus coupling sinteza hormoni; Side effects: rash, prurit (10-20%), agranulocitoza rare (0.1-0.5% - oprire IMEDIATA, hemograma baseline obligatoriu plus repeat la febra/tonsilita); hepatic crestere aminotransferaze (mild frecvent, severe rare); arthralgia, mialgia; vasculita ANCA-pozitiva rare; embriopatie T1 (aplasia cutis, choanal atresia, esophageal atresia, dysmorphic facies); cholestatic hepatitis rare. Propylthiouracil (PTU, Propycil) - alternativa selectiv; Doza initiala: 100-300 mg/zi impartit 3x/zi; Maintenance: 50-150 mg/zi; Indicatii PTU prima linie: sarcina T1 (metimazol teratogen embriopatie methimazole - aplasia cutis, choanal atresia, esophageal atresia, omphalocele, dysmorphic facies; switch metimazol T2-T3 prin PTU hepatic toxicitate cumulativa), thyroid storm (blocheaza T4-T3 conversie peripheral dincolo de blocare TPO), allergie metimazol; Avantaje: blocare aditionala T4-T3 deiodinase 1 peripheral (util storm), traversare placentara mai redusa (preferred T1); Side effects: hepatotoxicitate sever (rare dar fatal - fulminant hepatic failure necesita transplant hepatic; doza limitata 300 mg/zi maxim; functie hepatica baseline plus monitorizare obligatoriu); vasculita ANCA-pozitiva mai frecventa PTU vs metimazol; agranulocitoza rare; rash, prurit. Durata cura ATD: 12-18 luni initial (ATA preferred 12-18, ETA flexible 12-24); rate remisiune 30-50% dupa o cura; predictie remisiune: TRAb sub 2× ULN final cura, gusa mica, varsta tarzie, non-smoker, oftalmopatie absenta sau minimal, sex feminin; recidiva tipic 1-2 ani post-discontinuare necesita decizie tratament definitiv RAI/chirurgie versus cura repetata ATD selectiv.

Optiunea 2 - Iod radioactiv (RAI, I-131): Doze: 5-15 mCi calculat per dimensiune tiroida plus uptake 24h (fixed dose 10-15 mCi alternativ vs calculated dose 100-200 μCi/g tesut tiroidian); Mecanism: distrugere progresiva celule tiroidiene prin radiatie beta-emisiune I-131 cu actiune locala 1-2 mm penetrare; Actiune lenta: efect maxim 3-6 luni post-RAI; Avantaje: definitiv, simplu, eficient (90-95% cure rate at adequate dose); ambulator administrare cu izolatie limitata 1-2 zile; Dezavantaje: hipotiroidism inevitabil 50-80% la 1 an (necesita LT4 substituire lifelong); risc agravare oftalmopatia Graves (15-20% pacienti, mai mult la fumator - recomandare pre-RAI corticosteroid profilactic prednison 0.4-0.5 mg/kg/zi 1 luna tapering 2-3 luni la pacient cu oftalmopatie activa fumator); risc tireotoxicoza tranzitor cu storm rare pre-treatment ATD recomandat 4-8 saptamani pre-RAI selectiv (varstnici, cardiac compromise, severe hipertiroidism); Contraindicatii absolute: sarcina (RAI teratogen plus distrugere tiroida fetala), lactatie (1-2 saptamani pause minim, total 2 luni pause recomandat); Contraindicatii relative: oftalmopatia Graves activa severa (preferred ATD prelong sau chirurgie); copii varsta sub 5 ani (concern radiogenic carcinogenesis pe termen lung); planificare sarcina sub 6-12 luni (pause obligatoriu 6-12 luni post-RAI inainte sarcina); Pregatire pre-RAI: stop ATD 3-7 zile pre-RAI (pentru uptake adecvat); dieta low-iodine 1-2 saptamani pre-RAI (evitare contrast iodat CT, amiodarona, supplements iod, fructe de mare extreme); pregnancy test obligatoriu femei reproductive age; consimtamant informat. Optiunea 3 - Thyroidectomia totala (sau sub-totala): Tehnica: chirurgie endoscopic (minimal invasive cu cicatrice mica suprasternal) sau open clasic; thyroidectomia totala (preferred per ATA 2016/2020 - rezidual minim recurenta) vs sub-totala (rezidual 2-4 g lobectomy controlateral - risc recidiva 10-20%); Avantaje: curativ rapid (zile post-op); definitiv complet; util in gusa mare cu compresia traheal/esofagian, oftalmopatie severa (preferred per ETA 2018 alternativ RAI), sarcina T2 imposibilitate ATD, suspect malignitate cu nodul tiroidian focal, refuz RAI; Dezavantaje: chirurgie risc (hipoparatiroidism 1-2% permanent plus 10-20% tranzitor; paralizie laringeu recurent 1-2% unilateral, rare bilateral cu necesitate tracheostomy; hematoma postoperator cu compresia traheal urgent re-explore rare); cicatrice (estetic minor cu tehnica modern); hipotiroidism lifetime cu necesitate LT4; Pregatire pre-op: ATD 4-6 saptamani pre-op pana eutiroidian (TSH normalizat sau ușor suprimat plus FT4 normal); iodine Lugol 7-10 zile pre-op (reduce vascularizare tiroidian plus hormon synthesis acute pentru reducere risc storm intraoperator); β-blocant continuare pana 7-10 zile post-op (control simptomatic plus prevenire storm); pregnancy test femei reproductive age; consimtamant informat; consultatii oftalmologic preoperator daca orbitopatie.

Tratament adjuvant simptomatic: β-blocant non-selectiv preferred (propranolol, nadolol) - control simptome simptomatic (tahycardia, tremor, anxietate); reducere conversie T4-T3 peripheral (propranolol mai eficient vs metoprolol sau atenolol cardioselective); doza propranolol 40-160 mg/zi impartit (sau extended-release 80-160 mg/zi uniqe); continuare pana eutiroidian sau RAI/chirurgie definitiv complet; alternativa β-blocant cardioselectiv (atenolol, metoprolol) la pacient cu astm bronsic sever sau bradicardie; contraindicatii absolute β-blocant: bradicardie severa, bloc AV grad II-III, decompensare cardiaca acuta (relativa - cu monitorizare poate folosi); Iod inorganic (Lugol, KI saturated) - acut tireotoxicoza/storm (1h dupa ATD initial); pre-op pregatire chirurgie 7-10 zile; reduce vascularizare tiroidian plus hormon synthesis acute (Wolff-Chaikoff effect tranzitor); Glucocorticoid - tireotoxicoza crisis (block T4-T3 conversion plus alterare clearance plus tratament insuficienta suprarenala relativa); oftalmopatia activa moderate-severe (high-dose IV pulse methylprednisolone 500 mg/saptamana × 6 plus 250 mg/saptamana × 6 - EUGOGO preferred protocol); pre-RAI profilactic la pacient cu oftalmopatie activa fumator (prednison oral 0.4-0.5 mg/kg/zi 1 luna tapering 2-3 luni); Selenium suplementare - oftalmopatie usoara/moderata 200 μg/zi PO (sodium selenite preferred); EUGOGO trial 2011 beneficiu modest pe quality of life plus reducere progression; durata 6 luni; Teprotumumab (Tepezza) - IGF-1R monoclonal antagonist; aprobat FDA 2020 oftalmopatia Graves activa moderate-severe; 8 perfuzii IV Q3 saptamani (cumulative 8 perfuzii); reduce proptoza 2-3 mm plus diplopia; side effects: hyperglicemia (mai ales diabetics), muscle spasm, sensoryhipoacusia tranzitorie, infusion reactions; cost ridicat (~350.000 USD curs complet); disponibilitate limitata Romania prin compassionate use; Rituximab (anti-CD20, off-label) - refractary Graves orbitopathy moderate-severe; beneficiu modest contradictoriu in clinical trials; rare folosit; Plasmapheresis (TPE - therapeutic plasma exchange) - severe oftalmopatia activa refractary la corticosteroid plus teprotumumab; thyroid storm refractary la tratament medical maximal; rare folosit prin invaziv plus eficacitate tranzitorie. Tratament oftalmopatia Graves: faza activa (CAS peste 3): STOP fumat OBLIGATORIU (smoking creste risc oftalmopatie 7-8× plus reduce raspuns tratament); selenium 200 μg/zi (usoara-moderata); glucocorticoid IV pulse (moderate-severe activa - methylprednisolone EUGOGO protocol); teprotumumab IV (severe activa); radioterapia orbital 20 Gy fractionat (selectiv refractary cu predominant ophthalmoplegia restrictiva); lubrifianti oculari intensive plus protectie nocturnă (ointment); suport psihologic obligatoriu; faza inactiva reziduala (CAS sub 3 stabil 6-12 luni): chirurgie rehabilitative - decompression orbital pentru proptoza reziduala; strabismus surgery pentru diplopia reziduala; oculoplastic blepharoplasty pentru retractie palpebrala plus cosmetic restoration.

Sarcina cu Graves preexistent sau de novo - management complex: T1 (1-12 saptamani) - PTU prima linie (metimazol embriopatie teratogen contraindicat); doza PTU 50-150 mg/zi impartit; tinta FT4 high-normal sau usor crescut plus TSH suprimat (NU normalizare TSH - risc hipotiroidism fetal cu impact pe development cerebral fetal); monitor FT4/TSH/TRAb Q4 saptamani; T2-T3 (13-40 saptamani) - switch metimazol 5-15 mg/zi (PTU hepatic toxicitate cumulativa); continuare tinta FT4 high-normal; monitor TRAb T2-T3 (saptamani 20-24 si 30-32) pentru risc neonatal Graves (TRAb materni peste 3× ULN risc 5-10%); ecografie tiroidiana fetala plus Doppler artera tiroidiana fetala plus cordon ombilical (suspect TRAb crescut materni); neonatologul alertat antepartum pentru screening neonatal cordon plus zi 3-5 viata; Postpartum - continuare ATD ajustat (recidiva postpartum 70% in 1 an); β-blocant compatible alaptare; LT4 substituire daca hipotiroidism iatrogenic ATD over-treatment; RAI CONTRAINDICAT ABSOLUT in sarcina (teratogen plus distrugere tiroida fetala); pause 6-12 luni post-RAI inainte planificare sarcina; Chirurgie selectiv T2 doar daca necesar absolute: alergie ATD severa, esec medical, gusa mare cu compresia, suspect malignitate.

Stil viata - recomandari pacient cu Graves

Conform ATA, ETA, NHS, NICE plus Endocrine Society, pacient cu boala Graves beneficiaza de modificari stil viata adjuvante tratament medical. Dieta echilibrata cu iod adecvat: NU iod excess (evitare contrast iodat CT non-emergent, amiodarona daca alternativa cardiologic, supplements iod kelp/seaweed, fructe de mare extreme); NU restrictie iod severa (NU "low-iodine diet" except 1-2 saptamani pre-RAI prepratie); aport iod tinta 150 μg/zi adult (200-220 μg/zi sarcina); sare iodata standard recomandata; STOP fumat OBLIGATORIU - smoking creste risc Graves orbitopathy 7-8× plus reduce raspuns tratament plus crește progression severe; suport quitting smoking (counseling, nicotine replacement therapy, varenicline, bupropion); Somn 7-9 ore - hypothyroidism plus storm risc cu sleep deprivation severe; sleep hygiene standard (program fix, evitare cofeina seara, evitare ecrane 1h pre-somn, ambient racoros); melatonin selectiv suplementare 1-3 mg seara daca insomnia persistent; Reducere stres - stres declanseaza Graves plus storm; meditation, yoga, mindfulness, terapia cognitiv-comportamental, hobby relaxante; suport psihologic obligatoriu daca anxietate severa plus depresia; Exercitiu fizic adapted - NU intens pana eutiroidian (risc cardiac plus AFib); walking light, yoga, stretching faza activa; progressively crestere intensitate post-eutiroidian; sport competitiv DOAR post-eutiroidian stabil cu clearance cardiologic; Vaccinari curent - influenza anual, COVID booster per recomandari nationale, pneumococcal, zoster post-50 ani; concern reactivare/declanseaza Graves rare (vaccinare necesara totusi pentru protectia infectii precipitante storm); Suport psihologic - asociatii pacienti cu Graves (Asociația Pacienților cu Boli Tiroidiene Romania); grupe suport online; terapia cognitiv-comportamental daca anxietate severa plus depresia; education recunoaștere semne urgenta (storm, agranulocitoza, neuropatie optic in orbitopatia severa) plus actiune emergent (PUC apel, transport spital); Education recunoaștere semne urgenta - storm (febra inalta plus tahycardia extrema plus alterare constiență - transport emergent UPU); agranulocitoza ATD (febra plus tonsilita plus stomatita - emergent hemograma plus oprire ATD imediat); neuropatie optic in orbitopatia severa (pierdere acuitate vizual progresiva plus pierdere campului vizual - emergent oftalmologic); reactiv alergic ATD (rash extins plus angioedema plus dispnee - oprire ATD plus antihistaminic plus consult medical); Aprilie 2026 update protocoale ATA/ETA: integrare screening sarcina cu TRAb obligatoriu T2-T3 la antecedente Graves chiar eutiroidian curent; integrare scor GREAT (Graves Recurrent Events After Therapy) per ETA 2018 pentru decizie tratament definitiv RAI/chirurgie versus cura repetata ATD; integrare teprotumumab disponibilitate Romania prin compassionate use pentru oftalmopatia severa.

Monitorizare - profil tiroidian plus TRAb plus complicatii

Conform ATA, ETA, AACE plus Endocrine Society, monitorizarea pacientului cu Graves include profil tiroidian, TRAb plus complicatii. Pe ATD activ: TSH plus FT4 Q4-6 saptamani pana eutiroidian (3-6 luni tipic); apoi Q3 luni maintenance; FT3 selectiv (la pacient cu T3 toxicosis subtype 5-10%); TRAb baseline plus la 6 luni plus la 12 luni cura ATD (decide remisiune sau RAI/chirurgie - TRAb peste 2× ULN final cura indica predictie recidiva); functie hepatica baseline plus la 6 luni plus la febra/icter; hemograma baseline plus la febra/tonsilita (suspect agranulocitoza); CRP plus VSH selectiv suspect vasculita ANCA-pozitiva. Post-RAI: TSH plus FT4 Q4-6 saptamani primele 6 luni pana ajunge hipotiroidism (50-80% pacienti); apoi LT4 substituire cu titrare TSH 0.4-2.5 mUI/L tinta (mai stict 0.4-1.5 pediatric plus sarcina planning); TRAb la 6-12 luni post-RAI (clearance gradual); profil thyroid Q3 luni primii 2 ani apoi anual stable; oftalmologic exam Q3-6 luni primii 2 ani daca orbitopatie pre-existenta (concern agravare). Post-thyroidectomia totala: TSH plus FT4 Q4-6 saptamani primele 6 luni pentru titrare LT4 substituire (necesar lifelong); apoi anual stable; calciu plus PTH la 1 saptamana plus 1 luna plus 6 luni (suspect hipoparatiroidism); TRAb la 6-12 luni (clearance mai rapid vs RAI 3-12 luni); oftalmologic exam Q3-6 luni primii 2 ani daca orbitopatie pre-existenta. Monitorizare complicatii cronic: DEXA bone densitometry baseline plus anual (osteoporoza risc); lipidograma anual (modest scădere Graves activ); glicemia plus HbA1c anual (rezistenta insulin); ECG la palpitatii/AFib (anticoagulare urgent daca AFib); echocardiografie selectiv suspect cardiomyopathy thyrotoxic severe untreated; oftalmologic exam complete Q6 luni faza activa orbitopatie plus anual post-stabilizare; Aprilie 2026 - protocoalele ATA 2024 plus ETA 2023 recomanda integrare monitorizare TRAb sarcina la antecedente Graves chiar eutiroidian curent plus screening neonatal cordon plus zi 3-5 viata.

Grupe speciale - sarcina plus pediatrie plus varstnici plus situatii speciale

Conform ATA, ETA, Endocrine Society plus AACE, grupele speciale necesita abordare individualizata. Sarcina - management complex (PTU T1 pentru evitare embriopatie metimazole; switch metimazol T2-T3 prin PTU hepatic toxicitate cumulativa); monitor FT4 high-normal sau usor crescut plus TSH suprimat (NU normalizare TSH - risc hipotiroidism fetal); TRAb obligatoriu T2-T3 pentru predictie neonatal Graves; neonatologul alertat antepartum; RAI contraindicat absolut; chirurgie T2 selectiv daca necesar absolute. Postpartum - 1 an surveillance recidiva Graves (vulnerable perioada 70% recidiva); continuare ATD ajustat; β-blocant compatible alaptare; LT4 daca hipotiroidism iatrogenic; monitor TRAb plus profil tiroidian. Pediatrie - rare Graves 5%; preferred ATD cura prelungita 24-36 luni vs RAI (concern radiogenic carcinogenesis pe termen lung); chirurgie selectiv refractary sau gusa mare; rate remisiune mai mica pediatric vs adult (20-30%); transition la endocrinolog adult la 18-21 ani; impact pe creștere staturală plus puberty plus performanță scolara - reversibil post-eutiroidian. Vârstnici - cardiac complications dominant (AFib dominant, IC, angina pectorala); β-blocant initial control simptomatic plus anticoagulare AFib; RAI preferred majoritar prin convenience plus eficacitate (ATD agranulocitoza risc crescut varstnici); apathetic thyrotoxicoza paradoxal cu depresia plus apatia in loc anxietate plus agitatie; pierdere ponderala marcata; osteoporoza accelerata. Cardiac comorbiditate - cardio-thyrotoxicoza cu AFib plus IC plus cardiomyopathy thyrotoxic; β-blocant plus ATD plus anticoagulare AFib (warfarină sau DOAC cu doze crescute prin metabolismul accelerat); evitare amiodarona prin iod content plus risc AIT type 1/2; consultatii cardiologic plus endocrinolog coordonat. Sport intensiv - NU competiție pana eutiroidian (risc cardiac AFib plus storm); clearance cardiologic plus endocrinologic obligatoriu pre-retur sport competitiv; Donor renal/transplant candidate - Graves activ contraindicatie temporara transplant (necesitate eutiroidian stabil 6-12 luni pre-transplant); Sezon - Graves storm risc crescut sezon foarte cald (stres termic precipitant); recomandare hydratare extra plus aer conditionat plus evitare expunere extrema vara; Imunoterapie checkpoint inhibitor - Graves induced rare (mai des hipotiroidism); tratament standard ATD plus β-blocant; continuare imunoterapie posibila daca control eutiroidian; Amiodarona induced thyrotoxicosis (AIT) - tip 1 (Graves-like, iod-excess): metimazol high-dose 40-60 mg/zi; tip 2 (destruction toxic): glucocorticoid IV plus β-blocant; tip mixed: combinatie; chirurgie subtotala selectiv refractary; Marine-Lenhart syndrome - Graves plus nodul autonom; uptake heterogen; tratament combinatie ATD plus RAI sau chirurgie selectiv; IFN-α induced thyroid autoimmunity - Graves pattern (TRAb+) sau Hashimoto pattern (anti-TPO+); tratament standard ATD plus β-blocant; continuare IFN posibila daca control eutiroidian sub ATD.

Mituri vs realitate

Mit MUSAI 1: "TRAb pozitiv inseamna obligatoriu boala Graves activa care necesita tratament imediat" (ATA plus ETA - FALS - TRAb pozitiv izolat fara hipertiroidism CLINIC plus BIOCHIMIC NU defineste Graves activ; pseudo-pozitivitatea apare tiroidita postpartum, tiroidita silenta, Hashimoto cu Hashitoxicoza overlap, post-tratament Graves (RAI/chirurgie) cu TRAb persistent ani; necesita corelatie cu TSH suprimat plus FT4/FT3 crescut plus ecografie hipervascular plus scintigrafie uptake difuz crescut; tratament initiat doar la Graves activ confirmat per Synevo Romania, MedLife, Regina Maria, Bioclinica)

Mit MUSAI 2: "Iodul radioactiv vindeca complet Graves fara complicatii pe termen lung" (Cleveland Clinic plus Mayo Clinic - FALS - RAI vindeca hipertiroidism dar 50-80% pacienti dezvolta hipotiroidism la 1 an cu necesitate LT4 substituire lifelong; 15-20% pacienti agravare oftalmopatia Graves post-RAI mai ales fumator necesitand pre-RAI corticosteroid profilactic; rare tireotoxicoza tranzitorie cu storm pre-treatment ATD recomandat varstnici cardiac severe hipertiroidism; pause 6-12 luni planificare sarcina; pacienti necesita monitor lifelong TSH/FT4 prin substituire LT4 plus oftalmologic exam selectiv)

Mit MUSAI 3: "Antitiroidianele vindeca Graves la majoritatea pacientilor dupa 12-18 luni cura" (Endocrine Society plus ETA - FALS - rate remisiune ATD doar 30-50% dupa o cura 12-18 luni; 30-50% pacienti recidiveaza la 1-2 ani post-discontinuare ATD necesitand decizie tratament definitiv RAI/chirurgie versus cura repetata; predictori recidiva TRAb persistent peste 2x ULN la finalul curei, gusa mare, varsta tanara, smoker, oftalmopatie activa, sex masculin, polimorfisme genetice CTLA4/PTPN22; algoritm modern integreaza scor GREAT (Graves Recurrent Events After Therapy) per ETA 2018 pentru decizie individualizata)

Mit MUSAI 4: "Oftalmopatia Graves se rezolva singura cu tratamentul hipertiroidism fara terapie specifica" (NICE plus NHS plus EUGOGO - FALS - oftalmopatia Graves are evolutie independent de control hipertiroidism cu fază activa 1-3 ani urmata de stabilizare reziduala; tratament specific necesar in faza activa: STOP fumat OBLIGATORIU (smoking creste risc 7-8x plus reduce raspuns tratament); selenium 200 μg/zi usoara-moderata; glucocorticoid IV pulse methylprednisolone EUGOGO protocol moderate-severe activa; teprotumumab IV severe activa; radioterapia orbital selectiv; lubrifianti intensive; chirurgie rehabilitative faza inactiva reziduala doar dupa stabilizare 6-12 luni)

Mit MUSAI 5: "Sarcina cu Graves preexistent este sigura fara monitorizare speciala TRAb" (ATA plus Endocrine Society - FALS - sarcina cu Graves chiar eutiroidian curent necesita monitor TRAb T2-T3 obligatoriu prin transfer placentar TRAb materni cu risc neonatal Graves 5-10% la TRAb peste 3x ULN; ecografie tiroidiana fetala plus Doppler artera tiroidiana fetala plus cordon ombilical selectiv; neonatologul alertat antepartum pentru screening neonatal cordon plus zi 3-5 viata; PTU T1 (evitare embriopatie metimazole) plus switch metimazol T2-T3 (PTU hepatic toxicitate cumulativa); tinta FT4 high-normal NU normalizare TSH risc hipotiroidism fetal cu impact development cerebral)

Surse - ghiduri internationale plus laboratoare Romania

Surse principale Aprilie 2026: ATA (American Thyroid Association) ghiduri hipertiroidism 2016/2020/2024; ETA (European Thyroid Association) ghiduri Graves 2018/2023; Endocrine Society Clinical Practice Guidelines 2011; AACE (American Association of Clinical Endocrinologists); NICE (UK); NHS (UK); NCBI PubMed; Cleveland Clinic; Mayo Clinic; Societatea Romana de Endocrinologie; Ministerul Sanatatii Romania; Synevo Romania; MedLife; Regina Maria; Bioclinica; Medicover. Pe IngesT, accesul rapid la endocrinolog, medic medicina interna, ginecolog in sarcina sau ORL in compresia traheala, laboratoare specializate (Synevo Romania, MedLife, Regina Maria, Bioclinica, Medicover) este coordonat prin platforma cu telemedicina plus reminder-uri automate SMS pentru monitorizare TSH/FT4 Q4-6 saptamani in faza activa Graves sau anual post-tratament definitiv stabil. Aprilie 2026 - protocoalele actualizate ATA 2024 plus ETA 2023 plus Endocrine Society plus AACE confirma rolul fundamental al TRAb in diagnosticul Graves, predictia recidivei post-ATD si monitorizarea sarcinii cu antecedente Graves pentru predictie neonatal Graves.

Consultatii endocrinolog urgent la TRAb crescut peste 2.0 IU/L plus hipertiroidism activ (TSH suprimat plus FT4/FT3 crescut); consultatii medicina interna sau cardiologie pentru AFib plus IC asociate; oftalmolog pentru orbitopatia Graves activa (proptoza, diplopia, durere oculara, pierdere acuitate vizual emergent); ginecolog plus endocrinolog plus neonatolog in sarcina cu Graves (PTU T1, switch metimazol T2-T3, monitor TRAb T2-T3 obligator pentru predictie neonatal Graves); UPU emergent in tireotoxicoza crisis (storm) cu febra peste 40°C plus tahicardia extrema plus alterare constiență sau agranulocitoza ATD (febra plus tonsilita plus stomatita) sau neuropatie optic in orbitopatia severa (pierdere acuitate vizual progresiva). Pe IngesT, accesul rapid Aprilie 2026 prin platforma cu telemedicina plus reminder-uri SMS pentru monitorizare TSH/FT4 Q4-6 saptamani in faza activa Graves.